Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans

January 31, 2019

Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in the near future. We look forward to the first of this new data at the upcoming ASCO GU 2019 meeting from the ARCHES Trial: A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Alicia and Chuck establish the foundation for considerations in the future treatments in mHSPC.

Biographies:

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.



Related Content:

Small Cells, Big Worries